- Novavax shares attempt recovery with a 2.5% increase amid FDA approval delays.
- Analysts project significant upside potential with a high price target of $25.00.
- Current valuation suggests a possible downside, according to GuruFocus estimates.
Novavax Inc. (NVAX, Financial) experienced a modest rebound with shares climbing 2.5% to $6.15, following a six-day losing streak. Despite facing over a 25% decline year-to-date, the recent uptick is linked to the FDA's decision to delay the full approval of its COVID-19 vaccine, pending additional data. This postponement comes amid recent signals of a forthcoming approval. Notably, the stock currently holds a "BUY" rating from analysts, in contrast to a "HOLD" from other assessments.
Wall Street Analysts Forecast
In analyzing the one-year price targets from six financial analysts, the average target price for Novavax Inc. (NVAX, Financial) is projected at $17.67, with estimates ranging from a high of $25.00 to a low of $9.00. This average target represents a potential upside of 195.43% from the current trading price of $5.98. More in-depth forecast data can be viewed on the Novavax Inc (NVAX) Forecast page.
Brokerage Recommendations
According to the consensus among seven brokerage firms, Novavax Inc. (NVAX, Financial) holds an average brokerage recommendation of 2.3, which aligns with an "Outperform" designation. This rating is based on a scale from 1 to 5, where 1 represents a Strong Buy and 5 indicates a Sell.
GuruFocus Valuation Insights
The estimated GF Value for Novavax Inc. (NVAX, Financial) over the course of one year is calculated at $4.96. This suggests a potential downside of 17.06% from the latest price of $5.98. The GF Value is GuruFocus' appraisal of the stock's fair market value, derived from historical trading multiples, past business growth rates, and anticipated future business performance. Additional detailed data is available on the Novavax Inc (NVAX) Summary page.
